Key result
Elevated plasma copeptin at admission was independently associated with a significantly increased risk of three-month mortality (HR 2.44) in unselected emergency patients.
Why the study?
Does elevated copeptin predict short-, mid-, and long-term mortality in unselected patients >40 years old admitted to an inner-city hospital?
Cohort (n=1,320)
No
Does elevated copeptin predict short-, mid-, and long-term mortality in unselected patients >40 years old admitted to an inner-city hospital?
Hazard Ratio: 2.44 (95% CI 1.47–4.08)
Absolute Event Rate: 14.5% vs 3.2%
p-value: p=<0.01
In unselected emergency department patients over 40 years old, elevated plasma copeptin is a strong, independent predictor of short-, mid-, and long-term mortality.
May support risk stratification in unselected ED patients; leaves open clinical utility pending prospective trials.
BACKGROUND: Rapid risk stratification is a core task in emergency medicine. Identifying patients at high and low risk shortly after admission could help clinical decision-making regarding treatment, level of observation, allocation of resources and post discharge follow-up. The purpose of the present study was to determine short-, mid- and long-term mortality by plasma measurement of copeptin in unselected admitted patients. METHOD: Consecutive patients >40-years-old admitted to an inner-city hospital were included. Within the first 24 hours after admission, a structured medical interview was conducted and self-reported medical history was recorded. All patients underwent a clinical examination, an echocardiographic evaluation and collection of blood for later measurement of risk markers. RESULTS: Plasma for copeptin measurement was available from 1,320 patients (average age 70.5 years, 59.4% women). Median follow-up time was 11.5 years (range 11.0 to 12.0 years). Copeptin was elevated (that is, above the 97.5 percentile in healthy individuals).Mortality within the first week was 2.7% (17/627) for patients with elevated copeptin (above the 97.5 percentile, that is, >11.3 pmol/L) compared to 0.1% (1/693) for patients with normal copeptin concentrations (that is, ≤11.3 pmol/L) (P <0.01). Three-month mortality was 14.5% (91/627) for patients with elevated copeptin compared to 3.2% (22/693) for patients with normal copeptin. Similar figures for one-year mortality and for the entire observation period were 27.6% (173/627) versus 8.7% (60/693) and 82.9% (520/527) versus 57.5% (398/693) (P <0.01 for both), respectively.Using multivariable Cox regression analyses shows that elevated copeptin was significantly and independently related to short-, mid- and long-term mortality. Adjusted hazard ratios were 2.4 for three-month mortality, 1.9 for one-year mortality and 1.4 for mortality in the entire observation period. CONCLUSIONS: In patients admitted to an inner-city hospital, copeptin was strongly associated with short-, mid- and long-term mortality. The results suggest that rapid copeptin measurement could be a useful tool for both disposition in an emergency department and for mid- and long-term risk assessment.
No takes yet. Share an insight, caveat, or question.
Iversen et al. (2014) conducted a cohort in Unselected emergency admissions (n=1,320). Elevated copeptin (>11.3 pmol/L) vs. Normal copeptin (≤11.3 pmol/L) was evaluated on Three-month mortality (HR 2.44, 95% CI 1.47-4.08, p=<0.01). Elevated plasma copeptin at admission was independently associated with a significantly increased risk of three-month mortality (HR 2.44) in unselected emergency patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: